Skip to main content
. Author manuscript; available in PMC: 2023 Jan 4.
Published in final edited form as: Cell Metab. 2021 Dec 15;34(1):158–170.e5. doi: 10.1016/j.cmet.2021.11.013

Figure 7. Silencing Tox4 ameliorates hyperglycemia and glucose intolerance in db/db mice.

Figure 7.

(A-C) Liver Tox4 mRNA (A) and WB (B) with quantification (C) in 4-hr-fasted, 12-wk-old male WT and db/db mice.

(D-G) TOX4 inhibition in 12-week-old db/db male mice. Liver Tox4 mRNA (D); Blood glucose (E) (* p<0.05 by 2-way ANOVA); GTT (F) and AUC (G) at day 4 post viral injection; n=8 for each group.

(H) ITT at day 7 post viral injection. n=8 for each group.

(I-J) Hepatic protein levels were determined by WB (I) and quantification (J).

(K) Liver mRNA expression in mice killed at day 10 post virus transduction.

(L) Hematoxylin and eosin (H&E), PAS, and Oil Red O staining of liver sections from Ctrl sh and Tox4 sh treated db/db mice. Scale bar, 200 μm.

* p<0.05, ** p<0.01, *** p<0.001 compared with WT or Ctrl sh-treated mice, 2-tailed Student’s t-test. Data are presented as means ± SEM.